<DOC>
	<DOCNO>NCT02014870</DOCNO>
	<brief_summary>The primary objective determine dose level live , wild-type A/California/ H1N1 2009 virus appropriate safety illness/infectivity profile use influenza virus , challenge strain future intervention study . Illness parameter collect subject symptom score well physical examination . Virus parameter measure PCR cell culture assay ( perform VisMederi srl ) .</brief_summary>
	<brief_title>Safety Reactogenicity H1N1 Influenza Challenge Virus Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<criteria>1 . Male female age 1845 year inclusive . 2 . Able give write informed consent participate . 3 . Healthy , determine medical history , physical examination , vital sign , 12 lead ECG , clinical safety laboratory examination baseline , determine Investigator . 4 . Absent low level detectable preexist antibody influenza virus subtypes , include minimum challenge strain , determine HAI titre ≤ 10 prior challenge . 5 . Nonhabitual smoker ( habitual smoker person smoke 4 cigarette tobacco product weekly basis ) agree use tobacco product participation study . 6 . Females fulfil one follow criterion : 1 . At least one year postmenopausal ; 2 . Surgically sterile ; 3 . Will use oral , implantable , transdermal injectable contraceptive 30 day prior administration A/California/H1N1 2009 virus followup visit perform . 4 . Use another reliable form contraception approve Investigator ( e.g. , intrauterine device , female condom , diaphragm spermicide , cervical cap , use condom sexual partner sterile sexual partner ) time screen follow visit perform . 5 . Women childbearing potential must negative serum pregnancy test screen negative urine pregnancy test Day 1 . 7 . Comprehension study requirement , express availability require study period , ability quarantine 10 day attend schedule followup visit . 8 . Negative alcohol urine drug screening test prior enter quarantine . 9 . Being willing adhere prohibition restriction specify protocol 1 . Prior receipt influenza vaccine previous 2 year . 2 . Significant adulthood history seasonal hay fever seasonal allergic rhinitis perennial allergic rhinitis chronic nasal sinus condition chronic sinusitis . 3 . Abnormal nasal structure include septal deviation nasal polyp . 4 . Suffering asthma , bronchiectasis , emphysema , chronic obstructive pulmonary disease chronic lung disease . 5 . Pregnant breast feeding . 6 . Diastolic BP &lt; 50 &gt; 90 mmHg , systolic BP &lt; 100 &gt; 150 mmHg , pulse &lt; 50 &gt; 100 bpm rest 5 min . 7 . Current use use within last 7 day intranasal corticosteroid . 8 . Presence significant uncontrolled medical , neurological psychiatric illness ( acute chronic ) assess Investigator . This include , limit , institution new surgical medical treatment ( chronic condition ) , significant dose alteration uncontrolled symptom drug toxicity within 3 month screen reconfirm Day 1 prior challenge . 9 . Positive serology HIV1 HIV2 , HBsAg HCV antibody . 10 . Cancer treatment cancer , within 3 year , exclude basal cell carcinoma skin , allow . 11 . Presence immunosuppression medical condition may associate impaired immune responsiveness , include , limited , diabetes mellitus inflammatory bowel disease . 12 . Presently receive ( history receive ) precede 3month period prior screening , medication treatment may adversely affect immune system allergy injection , immune globulin , interferon , immunomodulators , cytotoxic drug drug know frequently associate significant major organ toxicity , systemic corticosteroid ( oral injectable ) azathioprine mercaptopurine . Topical corticosteroid except intranasal allow . 13 . Anticipated presence household contact document severe immunosuppression ( define CD4 &lt; 200/mm³ absolute neutrophil count &lt; 1500/mm³ ) , either result disease and/or therapy . 14 . Anticipated presence household contact age 5 year young , within 2 week follow challenge . 15 . Anticipated presence household contact age 65 year old , within 2 week follow challenge . 16 . Current professional activity carer healthcare worker return work within 2 week follow challenge . 17 . Anticipated presence pregnant household contact , within 2 week follow challenge . 18 . History anaphylactic type reaction egg egg protein . 19 . History GuillainBarré syndrome . 20 . History drug chemical abuse year study . 21 . Receipt investigational virus product nonregistered drug within 30 day prior challenge currently enrol investigational drug study intend enrol study within ensue study period . 22 . Receipt blood blood product 6 month prior challenge plan administration study period . 23 . Blood donation last 12 week . 24 . Acute disease within 72 h prior challenge , define presence moderate severe illness without fever ( determined Investigator medical history physical examination ) , presence fever ≥ 38ºC oral . 25 . Elevated white cell count 10.5 x 109/L absolute neutrophil count 7.5 x 109/L . 26 . Any condition , opinion Investigator , might interfere primary study objective . 27 . Habitual smoker ( habitual smoker person smoke 4 cigarette tobacco product weekly basis ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Influenza</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Virus</keyword>
	<keyword>H1N1</keyword>
	<keyword>Challenge</keyword>
	<keyword>Vismederi</keyword>
</DOC>